Virpax Reports on Progress of Envelta

Virpax Pharmaceuticals

BERWYN, PAVirpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced recent progress made in its Envelta development program. Envelta is the Company’s non-opioid pain product candidate for acute and chronic pain that is being funded under an in-kind grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

Dose ranging studies for Envelta in both rats and dogs were recently completed, and the intranasal administration of Envelta was well-tolerated and no adverse effects were observed. The data from these studies will be used in Virpax’s Investigational New Drug (IND) application to the FDA as well as to establish safe dosing for the first-in-human trials of Envelta.

“We are actively working with NCATS to complete the studies necessary to move this program forward. We are pleased with the results from these latest studies and remain on track to file the IND by the second quarter of 2024,” stated Anthony P. Mack, Chairman and CEO of Virpax.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  Harmony Biosciences Completes Enrollment of Phase 3 Registrational Intune Study in Idiopathic Hypersomnia